Tiziana Life Sciences – Clinical Study for September 17, 2020 – Posted in: Tiziana Life Sciences (TILS)

17/09/2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil Nasal Adminsteration of Foralumab is a potentially transformative approach for treating patients with COVID-19. New York/London, September 17, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious…

Tiziana Life Sciences – Patent Granted August 24, 2020 – Posted in: Tiziana Life Sciences (TILS)

24th August, 2020 Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Granted a Patent on Methods and Use of Anti-IL-6/IL-6 receptor Monoclonal Antibodies as Prophylactic and Therapeutic Interventions for Covid-19 and other pulmonary diseases Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the United States Patent and Trademark Office (“USPTO”) has granted a patent…

Tiziana Life Sci PLC (TILS) Change of Adviser July 4, 2019 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announces the appointment of Shore Capital Stockbrokers Limited as Broker, with immediate effect. This follows the acquisition of Stockdale Securities Limited by Shore Capital Markets Limited. For further enquiries: Tiziana Life Sciences plc +44 (0)20 7493 2853 Gabriele Cerrone, Chairman and founder …

Tiziana Life Sciences plc – PDMR dealings June 25, 2019 – Posted in: Tiziana Life Sciences (TILS)

New York/London, 25 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 24 June 2019, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought ordinary shares of nominal value 3p each in the capital of the Company, as set out below, following prior consultation with the Takeover Panel in relation to Note…

Tiziana Life Sci Plc (TILS) Article on Clinical Activity of OKT3 June 24, 2019 – Posted in: Tiziana Life Sciences (TILS)

Newly Published Article Reporting Clinical Activity of Orally Administered OKT3, a Mouse Anti-CD3 Monoclonal Antibody, in Moderate to Severe Ulcerative Colitis Patients, Supports Tiziana’s Oral Monoclonal Antibody Platform Third party research conducted by leading U.S. institutions to be published in a peer reviewed journal Crohn’s & Colitis 360 shows orally administered anti-CD3 resulted in anti-inflammatory gene expression with no serious treatment related adverse events up to a dose of 1 mg of OKT3 Tiziana’s…

Tiziana Life Sciences – Clinical Study for September 17, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences – Patent Granted August 24, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sci PLC (TILS) Change of Adviser July 4, 2019 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences plc – PDMR dealings June 25, 2019 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sci Plc (TILS) Article on Clinical Activity of OKT3 June 24, 2019 – Posted in: Tiziana Life Sciences (TILS)

Address

Contact

Social

LEGAL